Catalyst Wire Dossier Catalyst Wire Dossier
EMA withdrawal · 2009-12-31

EMA Refused: Rhucin (recombinant human C1-inhibitor) — Pharming Group N.V.

View source ↗

Summary

The EMA refused approval for Rhucin (recombinant human C1-inhibitor) by Pharming Group N.V. for angioedema, decision dated 31 December 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rhucin (conestat alfa)

Snippet

Status: Refused. Therapeutic area: Angioedema. MAH: Pharming Group N.V.. Decision date: 31/12/2009